Study to Assess Efficacy of Risedronate in Preventing Bone Loss in Postmenopausal Women Treated for Breast Cancer

Exclusion Criteria

• •Women presenting a history of osteoporotic fracture or a T score less than -2.5 at at least one measure site
• •Women presenting clinical signs of metastases
• •Having received other hormonal treatment in the last 3 months
• •Having received treatment by bisphosphonates, raloxifene, tamoxifen, parathormone, strontium ranelate, tibolone,calcitonin and corticosteroids at more than 5mg/d for 3 months in the last year
• •Presenting a known and untreated hyperthyroid
• •Presenting a known hyperadrenocorticism
• •Patients treated and followed for Paget's disease of bone
• •Presenting a untreated primary hyperparathyroid
• •Presenting an indication against risedronate (known hypersensibility to risedronate monosodium and/or one of its excipients, non-corrected hypocalcemia, pregnancy or breast feeding, severe renal insufficiency inferior to 30 ml/min)
• •Patients presenting malabsorption syndrome for glucose/galactose
• •Person participating in another clinical trial concerning a medicine susceptible to influence bone mass